290 related articles for article (PubMed ID: 26319324)
1. The role of glycyrrhetinic acid modification on preparation and evaluation of quercetin-loaded chitosan-based self-aggregates.
Du H; Liu M; Yang X; Zhai G
J Colloid Interface Sci; 2015 Dec; 460():87-96. PubMed ID: 26319324
[TBL] [Abstract][Full Text] [Related]
2. The synthesis, self-assembling, and biocompatibility of a novel O-carboxymethyl chitosan cholate decorated with glycyrrhetinic acid.
Du H; Yang X; Pang X; Zhai G
Carbohydr Polym; 2014 Oct; 111():753-61. PubMed ID: 25037412
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of quercetin and pH-responsive DEAE-chitosan carriers as drug delivery system for breast cancer treatment.
de Oliveira Pedro R; Goycoolea FM; Pereira S; Schmitt CC; Neumann MG
Int J Biol Macromol; 2018 Jan; 106():579-586. PubMed ID: 28807690
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of rod-like chitosan-quinoline nanoparticles as pH-responsive nanocarriers for quercetin delivery.
Rahimi S; Khoee S; Ghandi M
Int J Biol Macromol; 2019 May; 128():279-289. PubMed ID: 30695722
[TBL] [Abstract][Full Text] [Related]
5. Development of chitosan/halloysite/graphitic‑carbon nitride nanovehicle for targeted delivery of quercetin to enhance its limitation in cancer therapy: An in vitro cytotoxicity against MCF-7 cells.
Sabzini M; Pourmadadi M; Yazdian F; Khadiv-Parsi P; Rashedi H
Int J Biol Macromol; 2023 Jan; 226():159-171. PubMed ID: 36435458
[TBL] [Abstract][Full Text] [Related]
6. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
[TBL] [Abstract][Full Text] [Related]
7. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
Yu JM; Li YJ; Qiu LY; Jin Y
J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
[TBL] [Abstract][Full Text] [Related]
8. N-octyl-N-arginine-chitosan (OACS) micelles for gambogic acid oral delivery: preparation, characterization and its study on in situ intestinal perfusion.
Yu F; He C; Waddad AY; Munyendo WL; Lv H; Zhou J; Zhang Q
Drug Dev Ind Pharm; 2014 Jun; 40(6):774-82. PubMed ID: 23679668
[TBL] [Abstract][Full Text] [Related]
9. Preparation, characterization, and drug release in vitro of chitosan-glycyrrhetic acid nanoparticles.
Zheng Y; Wu Y; Yang W; Wang C; Fu S; Shen X
J Pharm Sci; 2006 Jan; 95(1):181-91. PubMed ID: 16315245
[TBL] [Abstract][Full Text] [Related]
10. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
Du H; Liu M; Yu A; Ji J; Zhai G
Int J Pharm; 2017 May; 523(1):427-438. PubMed ID: 28359815
[TBL] [Abstract][Full Text] [Related]
11. Novel self-aggregates of chitosan oligosaccharide grafted stearic acid: preparation, characterization and protein association.
Hu FQ; Li YH; Yuan H; Zeng S
Pharmazie; 2006 Mar; 61(3):194-8. PubMed ID: 16599258
[TBL] [Abstract][Full Text] [Related]
12. Enhanced delivery of doxorubicin to the liver through self-assembled nanoparticles formed via conjugation of glycyrrhetinic acid to the hydroxyl group of hyaluronic acid.
Wang X; Gu X; Wang H; Yang J; Mao S
Carbohydr Polym; 2018 Sep; 195():170-179. PubMed ID: 29804965
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q
J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734
[TBL] [Abstract][Full Text] [Related]
14. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting.
Lin A; Chen J; Liu Y; Deng S; Wu Z; Huang Y; Ping Q
Drug Dev Ind Pharm; 2009 Nov; 35(11):1348-55. PubMed ID: 19832635
[TBL] [Abstract][Full Text] [Related]
15. Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.
Lv Y; Li J; Chen H; Bai Y; Zhang L
Int J Nanomedicine; 2017; 12():4361-4370. PubMed ID: 28652738
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of chitosan/polyvinylpyrrolidone coated nanoporous γ-Alumina as a pH-sensitive carrier for controlled release of quercetin.
Nematollahi E; Pourmadadi M; Yazdian F; Fatoorehchi H; Rashedi H; Nigjeh MN
Int J Biol Macromol; 2021 Jul; 183():600-613. PubMed ID: 33932424
[TBL] [Abstract][Full Text] [Related]
17. Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel.
Wang X; Chen Y; Dahmani FZ; Yin L; Zhou J; Yao J
Biomaterials; 2014 Aug; 35(26):7654-65. PubMed ID: 24927684
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo anticancer efficacy potential of Quercetin loaded polymeric nanoparticles.
Baksi R; Singh DP; Borse SP; Rana R; Sharma V; Nivsarkar M
Biomed Pharmacother; 2018 Oct; 106():1513-1526. PubMed ID: 30119227
[TBL] [Abstract][Full Text] [Related]
19. Preparation, characterization and in vivo evaluation of pH sensitive, safe quercetin-succinylated chitosan-alginate core-shell-corona nanoparticle for diabetes treatment.
Mukhopadhyay P; Maity S; Mandal S; Chakraborti AS; Prajapati AK; Kundu PP
Carbohydr Polym; 2018 Feb; 182():42-51. PubMed ID: 29279124
[TBL] [Abstract][Full Text] [Related]
20. Ameliorating quercetin constraints in cancer therapy with pH-responsive agarose-polyvinylpyrrolidone -hydroxyapatite nanocomposite encapsulated in double nanoemulsion.
Samadi A; Pourmadadi M; Yazdian F; Rashedi H; Navaei-Nigjeh M; Eufrasio-da-Silva T
Int J Biol Macromol; 2021 Jul; 182():11-25. PubMed ID: 33775763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
